Docetaxel for Advanced Breast Cancer
Author Information
Author(s): V Dieras, B Chevallier, P Kerbrat, I Krakowski, H Roche, JL Misset, MA Lentz, N Azli, M Murawsky, A Riva, P Pouillart, P Fumoleau
Primary Institution: Institut Curie, Paris
Hypothesis
Is docetaxel effective as first-line chemotherapy for patients with advanced breast cancer?
Conclusion
Docetaxel at a dose of 75 mg/m² is confirmed to be an active agent in treating advanced breast cancer.
Supporting Evidence
- An overall response rate of 52% was achieved in evaluable patients.
- Grade 4 neutropenia occurred in 82% of patients.
- The median duration of response was 34 weeks.
Takeaway
This study tested a medicine called docetaxel to see if it helps women with advanced breast cancer. It worked for about half of the women who tried it.
Methodology
A phase II, multicentre, open-label, non-randomised study where patients received docetaxel intravenously every 3 weeks.
Potential Biases
Potential selection bias due to non-randomized design.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
39 women, median age 51 years, with advanced breast cancer.
Statistical Information
Confidence Interval
95% CI 33-70%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website